KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) EBT Margin (2016 - 2025)

Historic EBT Margin for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to 297.04%.

  • Nektar Therapeutics' EBT Margin fell 1434700.0% to 297.04% in Q3 2025 from the same period last year, while for Sep 2025 it was 181.81%, marking a year-over-year decrease of 10900.0%. This contributed to the annual value of 121.13% for FY2024, which is 1854000.0% up from last year.
  • According to the latest figures from Q3 2025, Nektar Therapeutics' EBT Margin is 297.04%, which was down 1434700.0% from 352.53% recorded in Q2 2025.
  • In the past 5 years, Nektar Therapeutics' EBT Margin registered a high of 23.91% during Q4 2024, and its lowest value of 736.47% during Q2 2022.
  • For the 5-year period, Nektar Therapeutics' EBT Margin averaged around 345.98%, with its median value being 297.04% (2025).
  • As far as peak fluctuations go, Nektar Therapeutics' EBT Margin tumbled by -2946700bps in 2022, and later skyrocketed by 4868600bps in 2023.
  • Over the past 5 years, Nektar Therapeutics' EBT Margin (Quarter) stood at 587.02% in 2021, then skyrocketed by 51bps to 288.16% in 2022, then surged by 39bps to 176.29% in 2023, then skyrocketed by 114bps to 23.91% in 2024, then tumbled by -1342bps to 297.04% in 2025.
  • Its last three reported values are 297.04% in Q3 2025, 352.53% for Q2 2025, and 443.3% during Q1 2025.